Overview

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Status:
Withdrawn

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

PF-04691502 is an inhibitor of PI3K and mTOR kinase. Exemestane is an aromatase inhibitor for the treatment of advanced breast cancer in women whose disease has progressed following tamoxifen therapy. The combination of PF-04691502 and exemestane might mitigate resistance to hormonal therapy and result in greater clinical benefit than exemestane alone in women with estrogen receptor positive advanced breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Estrogens
Everolimus
Exemestane
Sirolimus